Rapid Influenza Diagnostic Tests Market Worth Nearly $2 Billion, Globally, by 2030
Zion Market Research has published a new report titled “Rapid Influenza Diagnostic Tests (RIDT) Market by Patient (Adult and Pediatric); by Product (Influenza B RIDT and Influenza A RIDT); by End User (Research Laboratories, Diagnostics Centers, Hospitals and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast.
According to the report, The global rapid influenza diagnostic test market is growing at a CAGR of 9.8% during 2022–2030.
Influenza is major disease burden globally and early diagnosis and detection is crucial for emerging pandemic strains. A large number of virus detection tests are available which include virus isolation in cell culture, or influenza specific RNA detection using reverse transcriptase-polymerase chain reaction (RT-PCR) or direct antigen detection. Commercially, a wide range of rapid influenza detection test kits are available. In rapid influenza diagnostic test presence of influenza viral nucleoprotein antigen is detected to diagnose current influenza infection. Commercially used RIDTs can detect the infection within 30 minutes. These tests mostly use immunoassays to detect viral antigen. However some tests detect neuraminidase activity. Rapid detection tests help reduce blood tests and chest radiography in clinical settings.
The global rapid influenza diagnostic tests market growth is supported by various factors such as increasing demand for cost effective and rapid diagnostic tests, increasing government awareness programs to control influenza outbreaks, and technological advancements in manufacturing of diagnostic kits and immunoassay techniques, increasing geriatric population. Also, easy availability of test kits increasing awareness, and increasing healthcare expenditure in developing countries are factors projected to boost the market growth in the coming years. However, lack of skilled professionals may act as restraining factor for the market growth.
The global rapid influenza diagnostic tests market is categorized based on patient, product, end user and region. Based on product, market is segmented into influenza B RIDT and influenza A RIDT. In 2018, market was dominated by influenza A RIDT product segment and is anticipated to hold retain its dominance during the forecast period. Rising number of people suffering from influenza will support the growth of RIDT for influenza A product segment.
Based on patient, rapid influenza diagnostic tests market is categorized into adult and pediatric. Adult patient segment held largest revenue share in 2018 whereas pediatric patient segment will exhibit fastest growth during the forecast period. Growing risk of influenza infection in pediatric patients is projected to augment the pediatric segment growth.
Research laboratories, diagnostics centers, hospitals and others are end users of the rapid influenza diagnostic tests market. In 2018, hospitals were the leading end users for RIDT market. This is due to presence of developed infrastructure and large patient pool in hospitals.
At regional level, North America held the prominent revenue share of the global RIDT market in 2018. Factors such as government support and initiatives to control influenza outbreaks, increasing healthcare spending, growing awareness, and availability of technological advanced products support market growth in this region. Europe was second leading regional market. Asia Pacific region is projected to witness swift growth in the coming years for rapid influenza diagnostic tests (RIDT). This fast growth is attributed to growing awareness, increasing geriatric population base and increasing health care spending. Middle East and Africa will register slower growth compared to other regions due to poor infrastructure and poverty. Latin America is expected to register moderate growth in the coming years.
Major players included in the report are -
· DiaSorin S.p.A
· Becton
· Dickinson and Company
· SA Scientific
· CorisBioconcep
· Meridian Bioscience Inc.
· Analytik Jena
· Quidel Corporation
· Abbott
· Princeton BioMeditech Corporation
· Roche
The report segment of global rapid influenza diagnostic tests market as follows:
Global Rapid Influenza Diagnostic Tests Market: Product
· Rapid Influenza Diagnostic Test for Influenza A
· Rapid Influenza Diagnostic Test for Influenza B
Global Rapid Influenza Diagnostic Tests Market: By Patient
· Pediatric
· Adult
Global Rapid Influenza Diagnostic Tests Market: By End User
· Hospitals
· Diagnostics Centers
· Research Laboratories
· Other End Users
Global Rapid Influenza Diagnostic Tests Market: By Region
· North AmericaThe U.S.Canada
· EuropeFranceThe UKSpainGermanyItalyRest of Europe
· Asia PacificChinaJapanIndiaSouth KoreaSoutheast AsiaRest of Asia Pacific
· Latin AmericaBrazilMexicoRest of Latin America
· Middle East & AfricaGCCSouth AfricaRest of Middle East & Africa
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us — after all — if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49–322 210 92714 USA/Canada Toll-Free №1–855–465–4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com